NR-15779结核分枝杆菌、CDC1551、转座子突变体敲除池7(突变细菌)
In 2002, TARGET (Tuberculosis Animal Research and Gene Evaluation Taskforce) was formed to enable the modeling of human tuberculosis in multiple animal species using defined protocols and testing defined mutants of M. tuberculosis. In addition to animal modeling activities, a library of intragenic transposon mutants has been created and characterized.
There are 20 transposon mutant knock-out pools available from BEI Resources (NR-15773 to NR-15792) that are companion products to the DeADMAn DNA Microarray (available from BEI Resources as NR-18958). The DeADMAn DNA Microarray is used for identification of genes essential for the survival of a stress condition in an in vivo model system infection.
M. tuberculosis, strain CDC1551 transposon mutant knock-out pool 7 is reported to be a mixture of 21 genetically defined M. tuberculosis transposon mutants. Some of the transposon mutants in knock-out pool 7 are available individually (see Pool 7 components below).
Each vial contains approximately 1 mL of bacterial culture in Middlebrook 7H9 broth with OADC enrichment containing 100 ?g/mL cycloheximide and 20 ?g/mL kanamycin.
Components:
Description of Transposon Knock-Out Mutant | Strain CDC1551 Gene | Strain H37Rv Gene1 | BEI Resources Product Number2 |
---|---|---|---|
POSSIBLE CONSERVED MEMBRANE PROTEIN | MT0425 | Rv0412c | NR-17909 |
POSSIBLE AMIDOHYDROLASE | MT0498 | Rv0480c | NR-17920 |
PPE FAMILY PROTEIN | MT3247 | Rv3159c | NR-17923 |
HYPOTHETICAL PROTEIN | MT2934 | Rv* | NA |
CRISPR-ASSOCIATED PROTEIN | MT2886 | Rv2819c | NR-15022 |
HYPOTHETICAL PROTEIN | MT1783 | Rv1741 | NR-15027 |
PROBABLE MYCOBACTIN UTILIZATION PROTEIN | MT2963 | Rv2895c | NR-15031 |
PROBABLE CONSERVED INTEGRAL MEMBRANE PROTEIN | MT2040 | Rv1986 | NR-15035 |
PROBABLE ATP-DEPENDENT DNA HELICASE | MT3295 | Rv3201c | NR-14986 |
PE-PGRS FAMILY PROTEIN | MT1004 | Rv0977 | NA |
POSSIBLE GLYCOSYL TRANSFERASE | MT3034 | Rv2958c | NR-15457 |
PROBABLE MEMBRANE PROTEIN | MT3972 | Rv3857c | NR-15714 |
PROBABLE TRANSCRIPTIONAL REGULATORY PROTEIN | MT0605 | Rv0576 | NA |
HYPOTHETICAL PROTEIN | MT2876 | Rv2809 | NR-15458 |
CONSERVED HYPOTHETICAL PROTEIN | MT0282 | Rv0269c | NR-17584 |
PROBABLE MEMBRANE PROTEIN | MT2673 | Rv2597 | NA |
CONSERVED HYPOTHETICAL PROTEIN | MT0688 | Rv0659c | NR-18144 |
CONSERVED HYPOTHETICAL PROTEIN | MT0996 | Rv0968 | NR-15658 |
CONSERVED HYPOTHETICAL PROTEIN | MT3982 | Rv3869 | NR-14790 |
CONSERVED HYPOTHETICAL PROTEIN | MT2444 | Rv2375 | NR-15716 |
1Rv* - In some cases there is no M. tuberculosis, strain H37Rv homologue to the M. tuberculosis, strain CDC1551 gene | |||
2NA - Individual transposon mutant not available from BEI Resources but may be available from TARGET |
BEI Resources 由美国国家过敏和传染病研究所 ( NIAID )成立,旨在为研究 A、B 和 C 类优先病原体、新兴传染病病原体、非病原微生物和其他相关微生物材料提供试剂、工具和信息到研究界。BEI Resources 获取、验证和生产科学家进行基础研究和开发改进的诊断测试、疫苗和疗法所需的试剂。通过将这些功能集中在 BEI Resources 中,可以监控科学界对这些材料的访问和使用,并确保试剂的质量控制。
除了为传染病界提供材料外,BEI Resources 还鼓励和支持研究人员和机构的材料存放。使用 BEI Resources存放材料对研究人员和研究社区有许多优势,包括安全存储、社区访问和分发;同时保护存款人的知识产权。只要有需要,BEI 资源库将作为研究人员的资源进行维护。您在 BEI Resources 的存款是一项有助于未来研究的长期投资。
BEI Resources 自 2003 年起由美国典型培养物保藏中心 (ATCC) 根据合同管理。2016 年 5 月, ATCC获得了一份为期七年的继续管理 BEI Resources的合同。合同范围已扩大到更全面的研究目录材料,包括由其他政府支持的研究项目存放的材料,将提供给生物防御和新兴传染病科学界。真菌、寄生虫、载体和其他相关材料已添加到现有的细菌、病毒和毒素试剂中,涵盖 NIAID A、B 和 C 类优先病原体和 NIAID 指定的新发传染病病原体和生物。